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The clinical efﬁcacy of B cell targeting therapies highlights the pathogenic potential of B cells in
inﬂammatory diseases. Expression of Fc Receptor like 4 (FcRL4) identiﬁes a memory B cell subset, which
is enriched in the joints of patients with rheumatoid arthritis (RA) and in mucosa-associated lymphoid
tissue. The high level of RANKL production by this B cell subset indicates a unique pathogenic role. In
addition, recent work has identiﬁed a role for FcRL4 as an IgA receptor, suggesting a potential function in
mucosal immunity. Here, the contribution of FcRL4þ B cells to the speciﬁc autoimmune response in the
joints of patients with RA was investigated.
Single FcRL4þ and FcRL4- B cells were sorted from synovial ﬂuid and tissue from RA patients and their
immunoglobulin genes characterized. Levels of hypermutation in the variable regions in both pop-
ulations were largely consistent with memory B cells selected by an antigen- and T cell-dependent
process. Recombinant antibodies were generated based on the IgH and IgL variable region sequences
and investigated for antigen speciﬁcity. A signiﬁcantly larger proportion of the recombinant antibodies
generated from individual synovial FcRL4þ B cells showed reactivity towards citrullinated autoantigens.
Furthermore, both in analyses based on heavy chain sequences and ﬂow cytometric detection, FcRL4þ B
cells have signiﬁcantly increased usage of the IgA isotype. Their low level of expression of immuno-
globulin and plasma cell differentiation genes does not suggest current antibody secretion. We conclude
that these activated B cells are a component of the local autoimmune response, and through their RANKL
expression, can contribute to joint destruction. Furthermore, their expression of FcRL4 and their
enrichment in the IgA isotype points towards a potential role for these cells in the link between mucosal
and joint inﬂammation.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Rheumatoid Arthritis (RA) is a chronic autoimmune inﬂamma-
tory disease that affects ca. 1% of the human population. The
anti-inﬂammatory effect of depletion of B cells with the CD20-
targeting antibody rituximab conﬁrms a role of these cells inroup, Institute of Inﬂamma-
es, University of Birmingham
ingham, B15 2WD, UK.
oellner).
r Ltd. This is an open access articlemediating RA disease activity [1]. 60e80% of RA patients have B cell
responses characterized by the production of autoantibodies
(ACPAs) recognizing several citrullinated proteins, mainly ﬁbrin-
ogen, vimentin and a-enolase [2]. These humoral autoimmune re-
sponses are primarily composed of IgG but can also contain other
isotypes including IgA [3]. In a recent study, we found that im-
munoglobulins expressed by B cells isolated from the RA joint
exhibit a bias towards recognition of citrullinated autoantigens [4].
A growing body of data suggests that ACPAs can contribute to
disease by stimulating osteoclast differentiation, complement
activation and immune complex formation [5e8]. However, whilst
B cell depletion by the anti-CD20 antibody rituximab reduces RAunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Clinical characteristics of RA patients who provided synovial ﬂuid or synovial tissue.
RF, rheumatoid factor; CCP, cyclic citrullinated peptide; CRP, C reactive protein; ESR,
erythrocyte sedimentation rate, DAS28, disease activity score 28. More detailed
clinical characteristics can be found online in the supplementary data paper [27].
Synovial ﬂuid
samples
Synovial tissue
samples
Number 19 2
Disease duration (yrs); median (IQR) 3 (1.5e10) 28.5
Female; n (%) 14 (74) 1
Age yrs; median (IQR) 60 (47.5e65.5) 69.5
CRP (mg/l); median (IQR) 20 (13e57) 5.5
ESR (mm/h); median (IQR) 30 (15e55) 21
DAS28 CRP; median (IQR) 5.4 (4.6e6.2) 3.5
DAS28 ESR; median (IQR) 5.9 (5.1e6.7) 4.7
Swollen joint count of 28; median (IQR) 6 (2e10) 2
Tender joint count of 28; median (IQR) 7.5 (5e14.7) 7
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modulatory effects of rituximab do not necessarily coincide with
changes in autoantibody levels [10]. Therefore, the whole range of
contributions of B cells to disease pathology remains undeﬁned.
Multiple mechanisms are plausible, including autoantibody pro-
duction, antigen presentation and cytokine secretion [11,12].
We recently identiﬁed a subset of memory B cells in the RA
synovium, which expresses high levels of RANKL, a cytokine with
key roles both in bone destruction and development of lymphoid
structures [13e15]. This cytokine-producing B cell subset is deﬁned
by expression of Fc receptor-like 4 (FcRL4) on their surface. As sy-
novial RANKL expression is signiﬁcantly reduced under B cell tar-
geting therapy [16], removal of FcRL4þ B cells may explain some of
the autoantibody-independent effects of B cell depletion.
FcRL4 is a transmembrane proteinwith a high level of homology
to Fc receptors. In particular, it is closely related to FcgRIIB [17,18].
While the other members of the FcRL gene family are evolutionary
conserved, FcRL4 is restricted to higher primates. Initially, FcRL4
was thought to have an entirely inhibitory function on B cell re-
ceptor signaling. However, more recent data point towards an
additional role in sensitizing B cells to TLR9 mediated NFkB acti-
vation, suggesting that the consequences of FcRL4 ligation are
context dependent [19e21].
B cells expressing FcRL4 were ﬁrst described as a distinct
memory B cell subset in human tonsils [22,23]. These cells
accumulate in the epithelium of mucosa associated lymphoid
tissue (MALT) and are less frequently found in the B cell rich
regions of follicles and germinal centers [22,24]. Although
FcRL4þ B cells display an activated, highly proliferative pheno-
type [23], the antigens they recognize in the mucosa have not
yet been identiﬁed. There is little understanding of their
contribution to mucosal inﬂammation beyond the observation
that FcRL4 can act as a low afﬁnity receptor for IgA [25]. Given
that FcRL4þ B cells are also enriched in the RA joint and produce
cytokines that could contribute to joint destruction [13,14], we
hypothesized that these cells may recognize local citrullinated
autoantigens. Here, we investigated the immunoglobulin (Ig)
isotype and the characteristics of the Ig variable region genes
expressed in FcRL4þ B cells isolated from RA synovial ﬂuid and
tissue. Recombinant monoclonal antibodies were generated from
single-cell isolated transcripts, to determine whether the surface
Ig of FcRL4þ B cells can recognize citrullinated autoantigens.
Furthermore, we explored the functional role of FcRL4þ B cells
by comparing their transcriptional proﬁle to FcRL4- B cells
sorted from the same joints.2. Material and methods
2.1. Patients
A total number of 19 synovial ﬂuid (SF) and 2 synovial tissue (ST)
samples were included in this study. Samples were obtained from
patients fulﬁlling 1987 American College of Rheumatology (ACR)
criteria for RA [26]. ST samples were obtained at the time of joint-
replacement surgery. A summary of patient characteristics is
shown in Table 1. A more detailed set of characteristics including
current and recent immunosuppressive therapy is shown in the
supplementary table 1 [27]. The cell numbers yielded from indi-
vidual samples was too low to perform all experiments with ma-
terial from the same patients. The samples used for the individual
experiments are identiﬁed in supplementary table 1 [27]. The study
was conducted in compliance with the Helsinki declaration, ethical
approval was obtained from the local ethics committee and all
subjects gave informed, written consent.2.2. Flow cytometry and single B cell sorting
Synovial ﬂuid was incubated with 1000 U ml1 hyaluronidase
(HyalaseTM, Wockhardt UK Ltd) at 37 C for 15 min to reduce vis-
cosity. Mononuclear cells were isolated from SF using density
gradient centrifugation and from mechanically dissociated ST as
previously described [28]. Cells from 4 SF and 2 ST samples (Suppl
table 1; patients 1e6) [27] were stained for ﬂow cytometry with
mouse monoclonal antibodies against CD19 (Biolegend 302234)
and FcRL4 (Biolegend 340204). A total of 96 single B cells from
CD19þFcRL4þ and CD19þFcRL4- populations were sorted from
each SF and ST samples using a MoFlo cell sorter (Dako) into 96-
well PCR plates as previously described [29,30]. Purity of sorted
cells was in excess of 95%.
For detection of IgA B cell receptors, mononuclear cells were
isolated from SF of 11 further RA patients (Suppl. table 1; patients
7e17) [27]. Surface receptor-bound antibodies were ﬁrst removed
by incubating SF B cells in 0.1 M glycine buffer at pH3 for 90 s. Cells
were washed, labeled with antibodies to IgA (Miltenyi), FcRL4
(Biolegend) and CD19 (Biolegend) and analyzed on a Cyan ADP ﬂow
cytometer (Beckman).
2.3. PCR ampliﬁcation and expression vector cloning
cDNA from the single sorted FcRL4þ and FcRL4- B cells was
synthesized in a total volume of 15 ml in the original 96-well PCRplate
using the SuperScript III RT (Gibco Invitrogen). Individual IgH (g, a or
m) and IgL chain (k or l) gene rearrangements were ampliﬁed
independently, using the cDNAas template, by two successive rounds
of PCR (50 cycles each) using primers as previously described [29,30].
For identiﬁcation of Ig isotypes, ampliﬁcation of IgH chains with
reverse primers speciﬁc for the constant regions of all human Ig
classes and sequencing was used. Cloning of the Ig genes into
expression vectors was performed as described before [29,30].
Brieﬂy, digested PCR products were cloned in frame into expression
vectors containing human Igg1, Igk1, or Igl1 constant regions.
Ligation reactions were performed using the quick ligase kit (New
England Biolabs, Inc.). Expression vectors were transformed into
DH5a bacteria (Gibco Invitrogen) and sequentially isolated using
QIAprep Spin Miniprep kit (Qiagen). All PCR products were
sequenced after cloning to conﬁrm identity with the original PCR
product and to ensure that clones with mutations introduced by the
error-prone Taq polymerase were excluded from the analyses.
2.4. Ig gene sequence analysis
Matching IgH and IgL amplicons obtained from individual
cells were sequenced (Euroﬁns MWG Operon) and analyzed for
K. Amara et al. / Journal of Autoimmunity 81 (2017) 34e4336Ig gene usage, the complementarity-determining region 3
(CDR3) features, and number of V gene somatic hypermutations
(SHMs) by IgBLAST comparison (http://www.ncbi.nlm.nih.gov/
igblast/) and ImMunoGeneTics (IMGT) information system,
(http://imgt.cines.fr). The IgH CDR3 length was determined as
indicated previously [31]. Percent V gene mutation was calcu-
lated based on the number of V gene nucleotide mismatches
determined by IgBLAST/IMGT, and the length of the V gene that
was sequenced. The number of positively and negatively
charged amino acids was determined for each IgH CDR3 region.
Numbers of V gene SHMs were counted for framework regions
(FWR1, FWR2, and FWR3) and CDRs (CDR1 and CDR2) inclu-
sively. Replacement (R) and silent (S) mutation frequencies in
FWRs and CDRs were calculated for each region based on the
absolute number of V gene nucleotides in all analyzed se-
quences as deﬁned by IMGT. IgG isotype subclasses were
determined using the IMGT database. Immunoglobulin Analysis
Tool (IgAT) was used to calculate the probability of antigen-
driven selection within the Ig repertoire of the monoclonal
antibodies as previously described [32].2.5. Antibody production and puriﬁcation
Monoclonal antibodies were produced by transient transfection
in high-density suspension cultures of Expi293F™ cells using pol-
yethylenimine (PEI)-Max (Polysciences) as transfection agent in a
total of 38 mg of vector DNA (19 mg of IgH and corresponding IgL,
each) as recommended by the manufacturer (Gibco Invitrogen).
Monoclonal antibodies were puriﬁed on Protein G Sepharose 4 Fast
Flow (GE Healthcare) and eluted with 0.1 M glycine buffer, pH 3.0,
into neutralization buffer (1 M Tris-HCl, pH 8.0). Monoclonal anti-
body concentrations were determined by antiehuman IgG1 ELISA
using human monoclonal IgG1 as standard (Sigma-Aldrich) as
previously described [29,30].2.6. Antibody speciﬁcities
2.6.1. Assessment of IgG antibody reactivity against citrullinated
peptides
The Antiea-enolase reactivity was determined by ELISA as
described, brieﬂy: 96-well Nunc plates were coated with
2.5 mg ml1 of the a-enolase peptide 1 in its native (REP-1) or
citrullinated (CEP-1) form [33,34]. Anti-vimentin and -ﬁbrinogen
reactivity was determined by ELISA as described previously [35].
In brief, streptavidin-coated high bindingecapacity 96-well
plates (Thermo Fisher Scientiﬁc) were coated with 1 mg ml1
of biotinylated vimentin (amino acids 60e75) or ﬁbrinogen
(amino acids 36e52) peptides in their native and citrullinated
forms. In all ELISAs, puriﬁed monoclonal antibodies were diluted
in blocking buffer and used at a concentration of 5 mg ml1. HRP-
conjugated goat antiehuman IgG (Jackson ImmunoResearch
Laboratories, Inc.) was used as the detecting antibody and
visualized using the chromogenic substrate 3,30,5,50-tetrame-
thylbenzidine (Bio-Rad Laboratories). Reactivity was detected at
450 nm with a reference of 650 nm. A standard curve con-
structed with a serum sample positive for speciﬁc antigen was
included on each plate and was further used to translate OD
values to AU values, where the control maximum corresponds to
1000 AU. The AU values were divided by antigen-speciﬁc
detection cutoffs based on prior experience with a larger set of
clones. Reactivity with the synthetic cyclic citrullinated peptides
(CCP2) was determined with the commercially available ELISA
kit (Eurodiagnostica).2.7. Gene expression analysis
RNA sequencing was carried out on sorted FcRL4þ and FcRL4- B
cells from 4 additional SF samples (supplementary data paper table
1) [27]. Synovial ﬂuid mononuclear cells were sorted into CD19þ/
FcRL4þ and CD19þ/FcRL4- populations into PBS supplemented
with 10% BSA/5 mM EDTA. RNA was isolated using the PicoPure
RNA extraction kit (ThermoFisher). Preampliﬁcation prior to Illu-
mina Truseq library preparationwas performed using the SMARTer
ampliﬁcation using olig(dT) primed reactions (Clontech cat#
635001). Library prep was carried out using the Illumina TruSeq
Stranded prep kit and sequenced on the Illumina HiSeq 2000/2500
platform (100 bp read length, paired end) using reagent kit v3.
We initially analyzed the data using the Tuxedo suite [36], using
Bowtie version 2.1.0, Tophat v2.0.9 and Cufﬂinks v2.1.1 with
genome assembly GRCh37, ﬁnding predominantly Ig gene seg-
ments differentially expressed. The ﬁnal analysis, shown in the
ﬁgure, employed alignment to the GRCh38 genome build by STAR
2.4.0g1 [37] and gencode v21 exon junctions, giving 13e23 million
mapped reads per sample. We then calculated RPKM expression
values using rpkmforgenes [38], version 13 Mar 2015 with options
-midread -readcount -rmnameoverlap. P-values were calculated
using DESeq2 [39], using all genes except microRNA and snoRNA
genes, comparing 4 FCRL4þ against 4 FCRL4- samples. We used a
5% Benjamini-Hochberg false discovery rate cutoff. For Ig gene
segment expression, we used gencode v22 annotation and selected
features with gene_type IG_V_gene, IG_J_gene, IG_C_gene or
IG_D_gene, and ran rpkmforgenes with option -midread.
2.8. Other statistical analyses
Speciﬁc statistical tests used are indicated in the ﬁgure legends.
Differences were considered to be statistically signiﬁcant at values
of p < 0.05. All statistical analyses were performed by Prism soft-
ware version 5.0 (GraphPad Software).
3. Results
3.1. FcRL4þ B cells immunoglobulin genes are enriched for the IgA
isotype
Single FcRL4þ and FcRL4- CD19þ B cells were isolated from
synovial ﬂuid (n¼ 4) and synovial tissue (n¼ 2) fromACPA positive
patients with RA (Fig. 1A). Analysis of the Ig isotypes at the gene
expression level demonstrated that overall the majority of both
FcRL4þ and FcRL4- B cells express IgG (Fig. 1B and supplementary
table 2) [27]. However, a signiﬁcantly higher proportion of FcRL4þ
cells expressed IgA1 compared to FcRL4- B cells (P ¼ 0.011).
Conversely, IgM was expressed in a lower proportion of FcRL4þ B
cells compared to FcRL4- B cells (P ¼ 0.039). This enrichment of
cells expressing IgA B cell receptors in the FcRL4þ subset was also
observed at the protein level, by ﬂow cytometry (Fig. 1C).
3.2. Synovial FcRL4þ B cells are clonally diverse
From the total number of the individually sorted B cells, Ig
variable regions of heavy (VH) and light (VL) chain transcripts were
successfully ampliﬁed by RT-PCR from 346 B cells (180 from FcRL4þ
cells and 166 from FcRL4- B cells; supplementary data paper table
2) [27]. Analysis of the variable regions showed that the Ig reper-
toire was highly diverse in both FcRL4þ and FcRL4- B cells with the
majority of the functional Ig genes being represented in the two B
cell subsets (Fig. 2A and supplementary data paper tables) [27].
Nevertheless, VH1-69 was over-represented in the FcRL4þ B cell
population (P ¼ 0.047), used by 10.5% of FcRL4þ cells compared to
Fig. 1. FcRL4þ B cells are enriched for the IgA Ig subclass. (A) Individual FcRL4þ and FcRL4- CD19þ B cells were sorted for subsequent analysis of their immunoglobulin genes. (B)
PCR products of IgH chains were sequenced with reverse primers speciﬁc for the constant regions of all human Ig classes and the distribution of Ig subclasses in single sorted
FcRL4þ and FcRL4- B cells was determined using IMGT database. P values were calculated by c2 test and corrected for multiple comparisons by the method of false discovery rates.
(C) Synovial ﬂuid mononuclear cells from RA patients were brieﬂy washed with an acidic buffer (pH 3) to remove externally receptor-bound antibodies and stained for CD19, FcRL4
and IgA. P values were determined by Wilcoxon rank sum test.
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the FcRL4þ B cells compared to FcRL4- B cells (P ¼ 0.039 after
correction for multiple comparison).
Further analysis of the heavy chain sequences showed that CDR3
features did not signiﬁcantly differ between FcRL4- and FcRL4þ B
cells in terms of amino acid length or frequency of charged residues
(Fig. 2B).3.3. Both FcRL4- and FcRL4þ B cells are generated under antigen-
mediated selection
Antigen-speciﬁc B cell receptor (BCR) genes undergo afﬁnity
maturation, typically in the germinal centers, whereby high-afﬁnity
B cells accumulate SHMs in their variable region genes [40]. In this
study, analysis of SHMs in individual Ig VH and VL genes showed
that FcRL4þ and FcRL4- B cells had accumulated equivalent levels
of SHMs (Fig. 3A and supplementary data paper table 2) [27].
Based on the frequencies of productive mutations (i.e. the
replacement to silent (R/S) mutation ratios) being higher for CDRs
compared to FWRs (Fig. 3B) the notion of antigen-mediatedFig. 2. Investigation of immunoglobulin characteristics of FcRL4þ and FcRL4- B cells. (A
were sequenced and analyzed by IgBLAST and IMGT/V-QUEST for gene segment repertoire
acid composition: average length of CDR3s in amino acids, and the mean number of positive
c2 test and corrected for multiple comparisons by the method of false discovery rates.selection in germinal centers could be substantiated in both sy-
novial FcRL4þ and FcRL4- B cells.
Additionally, sequences were tested for antigen driven selection
using the IgAT Analysis Tool [32] to calculate the probability of
antigen-driven selection based on somatic mutation analysis. A
similar proportion of sequences from the FcRL4þ and FcRL4- B cell
subsets (24.8% and 29.7%, respectively) displayed evidence of
antigen-driven selection (Fig. 3C). Taken together, molecular anal-
ysis of the Ig genes of both synovial FcRL4þ and FcRL4- B cells
suggests that cells in both populations have been differentiated in
response to antigen-mediated selection and undergone SHMs and
afﬁnity maturation in the context of T cell-dependent immune
reactions.3.4. Synovial FcRL4þ B cells contribute to the immune response
directed against citrullinated autoantigens
We have previously demonstrated an enrichment of B cells with
speciﬁcity towards candidate citrullinated autoantigens in the SF of
ACPAþ RA patients [4]. Here, the hypothesis that joint-derived B). Ig heavy chain variable (VH) genes of individually sorted FcRL4þ and FcRL4- B cells
usage. (B) Characteristics of IgH complementarity determining region 3 (CDR3) amino
ly and negatively charged amino acids in the CDR3 regions. P values were calculated by
Fig. 3. Mutational analysis in FcRL4þ and FcRL4- B cells. (A) Comparison of the absolute numbers of somatic mutations in individual heavy chain variable (VH) and light chain
variable (VL) genes of the antibodies generated from FcRL4þ and FcRL4- B cells. (B) Frequencies of replacement (R) and silent (S) mutations in the complementarity determining
regions (CDRs) and framework regions (FWRs) of VH regions of FcRL4þ and FcRL4- B cells. The R/S ratios are indicated below the respective graphs. (C) Immunoglobulin Analysis
Tool (IgAT) analysis to calculate the probability of antigen-driven selection based on somatic mutation analysis. The ratio of replacement mutations in CDR1 and CDR2 (RCDR) to the
total number of mutations in V region (MV) was plotted against MV for the FcRL4þ and FcRL4- B cells. The dark and the light grey area indicate the 90% and 95% conﬁdence limits for
the probability of random mutations, respectively. A data point outside these areas represents a sequence that was identiﬁed as having been selected in an antigen driven process.
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enriched in the FcRL4þ subset was addressed. For this purpose, the
IgH and matching IgL chains from both FcRL4þ and FcRL4- B cells
sorted fromACPAþ patients were cloned and transiently expressed,
generating recombinant monoclonal antibodies from 36 FcRL4þ B
cells and 27 FcRL4- B cells (Fig. 4 and supplementary table 2) [27].
The recombinant monoclonal antibodies were tested for reactivity
towards native and citrullinated peptides derived from a-enolase,
ﬁbrinogen and vimentin. Eight antibodies were identiﬁed as spe-
ciﬁc for citrullinated antigens and, interestingly, all of these were
derived from cells belonging to the FcRL4þ subset (P ¼ 0.018)
(Fig. 4A and supplementary table 2) [27].
A summary of the characteristics of the antibodies binding cit-
rullinated proteins is also shown in a supplementary table in the
supplementary data-only manuscript [27]. (Fig. 4 and supplemen-
tary table 2).
Overall, the investigation of the speciﬁcity of synovial FcRL4þ B
cells for candidate autoantigens showed that these B cells are acomponent of the autoimmune response to several well-
characterized RA-associated, citrullinated autoantigens.
3.5. FcRL4þ and FcRL4- synovial B cells have distinct gene
expression proﬁles
mRNA from sorted FcRL4þ and FcRL4- B cells from SF of
ACPAþ RA patients was analyzed by RNA-seq. Data shown in Fig. 5A
and B represent the comparison of gene expression between
FcRL4þ and FcRL4- B cells. Initial analysis showed that a large
proportion of the signiﬁcant differences in gene expression were
found in the immunoglobulin heavy and light chain genes. For
clarity, therefore, the immunoglobulin genes are shown in a sepa-
rate plot (Fig. 5A) with FcRL4þ B cells expressing consistently lower
levels of Ig genes, suggesting that these cells are not enriched in
cells differentiating towards antibody secreting cells. Fig. 5B shows
a scatterplot of the remaining expressed genes, with the genes
signiﬁcantly different after application of the Benjamini-Hochberg
Fig. 4. Heatmaps showing the antigen speciﬁcity of recombinant monoclonal antibodies derived from FcRL4þ (A) and FcRL4- (B) B cells. Monoclonal antibodies were
produced by transient transfection in high-density suspension cultures of Expi293F™ cells using PEI-Max. Reactivity with citrullinated peptides was ﬁrst assessed by use of the
commercial cyclic citrullinated peptide (CCP2) test. Reactivity to deﬁned B cell epitopes was then assessed by peptide ELISA for three deﬁned citrullinated peptides and their
matching arginine unmodiﬁed controls. These were, citrullinated a-enolase peptide 1 (CEP-1), citrullinated vimentin (cit-vim 60e75) and ﬁbrinogen (cit-ﬁb 36e52). The corre-
sponding control peptides were REP-1, arg-vim 60e75 and arg-ﬁb 36e52 respectively. The FcRL4þ subset is enriched for B cells speciﬁc for citrullinated autoantigens (P ¼ 0.018). y,
Peptides are designated by their abbreviated protein names (vim for vimentin) followed by the positions of the ﬁrst and last amino acid. cit, citrulline-containing peptides; arg,
native arginine-containing peptides. P value was calculated by Fisher's exact test.
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labeled in color.
Expression levels of genes previously described as over or
under-expressed in SF and tonsillar FcRL4þ B cells were analyzed
without the above stringent correction for multiple comparisons,
and shown in Fig. 6, respectively, showing very good agreement
with the existing data, also conﬁrming the overexpression of
RANKL in RA FcRL4þ B cells we and others have previously re-
ported [14,23]. A number of further genes involved in immune
function were found to be upregulated in FcRL4þ B cells here
consistent with ﬁndings from previous work by us and others.
These include CCR1 and CCR5, (receptors for pro inﬂammatory
chemokines which may explain the localization of the FcRL4þ B
cells at sites of inﬂammation) and FcRL5 (which is closely related to
FcRL4 and has been suggested to have IgG binding activity) [25].
CD11c is very highly expressed in FcRL4þ B cells and this may affectadhesion and complement binding of FcRL4þ B cells.
Overall, FcRL4þ B cells showed a depletion of plasma cell
associated genes when compared with the FcRL4- fraction.
Comparative under-expression of transcription factors such as
BLIMP-1 and XBP1 in FcRL4þ B cells again supports the view that
these cells are not in process of differentiating towards plasma cells,
even though they were enriched for the characteristic speciﬁcities
of RA autoantibodies.
4. Discussion
Synovial FcRL4þ B cells are an activated B cell population
expressing high levels of RANKL, a key cytokine driving bone
erosion and development of lymphoid structures [15]. Hence,
FcRL4þ B cells represent a potentially pathogenic B cell subset
capable of contributing to the immunopathology of RA.
Fig. 5. Synovial ﬂuid FcRL4þ and FcRL4- B cells differ in their gene expression proﬁles. FcRL4þ and FcRL4- B cells were sorted from RA patients' synovial ﬂuid. Their gene
expression proﬁle was determined by RNAseq. Scatter plots show the expression of individual Ig segments (A) and further differentially expressed genes at the genome-wide level
(<5% FDR, DESeq2) after Benjamini-Hochberg correction (B) for the two groups of B cells. The RNA-seq data has been deposited at Gene Expression Omnibus with accession number
GSE94897.
Fig. 6. Expression levels of genes previously described as over- or under-expressed in synovial ﬂuid and tonsillar FcRL4þ B cells. (<5% FDR, DESeq2) A) overexpressed in FcRL4þ B)
underexpressed in FcRL4þ B cells.
K. Amara et al. / Journal of Autoimmunity 81 (2017) 34e4340FcRL4þ B cells were ﬁrst identiﬁed in tonsils, where they
accumulate in the vicinity of the epithelium [22,41]. Furthermore, a
small population of these cells was found in the spleen and in
reactive lymph nodes [22]. There is little understanding of theirfunction in MALT, but it has become clear that while they are highly
proliferative, they show no expression of transcription factors
associated with B cell differentiation towards plasma cells [41].
FcRL4 can act as a low afﬁnity IgA receptor; this may be a feature of
K. Amara et al. / Journal of Autoimmunity 81 (2017) 34e43 41the role of FcRL4þ B cells in the MALT and potentially also in the
joints [25].
This study represents the ﬁrst investigation of the role of
FcRL4þ B cells in the autoimmune response operating in the
rheumatoid joints. Analysis of Ig gene sequences of synovial
FcRL4þ B cells showed a high level of somatic hypermutation,
supporting the view that these cells are post-germinal center
memory B cells that have been selected in an antigen and T cell
dependent context. Isnardi et al. [42] described an autoreactive B
cell population in the peripheral blood of patients with RA, which
shares a low level of CD21 expressionwith the FcRL4þ B cell subset.
However, the cells they described were naïve B cells with germline
immunoglobulin variable gene segment arrangement. There was
no evidence for over-expression of either FcRL4 or RANKL [42] and
these cells are clearly distinct from the memory B cells investigated
in this project. Furthermore, a population of CD21 low/CD11c high B
cells has been observed in peripheral blood of patients with a
number of chronic diseases and in advanced age (reviewed by
Thorarinsdottir et al. [43]). FcRL4þ cells were not detected in the
majority of peripheral blood samples from RA patients, [14].
However, since CD21 low/CD11c high memory B cells share several
surface markers with the cells we have investigated, it is possible
that they are the precursors of the FcRL4þ B cells we observed in RA
joints.
The repertoire of Ig gene segments forming the variable region
of B cell receptors was highly diverse in both FcRL4þ and FcRL4- B
cells (Fig. 1B). However, there was a statistically signiﬁcant
enrichment of usage of VH1-69 in the FcRL4þ B cell subset. VH1-69
is a gene segment that has previously been associated with auto-
immune diseases and is often a component of the variable region of
the gene coding for rheumatoid factor [44]. In hepatitis C infected
patients with cryoglobulinaemia a potentially related, IgM
expressing B cells population has been shown to use VH1-69 [45].
Conversely, VH3-23 was signiﬁcantly over-represented in the
FcRL4- B cells, thismay be due to an overall high frequency of B cells
using the VH3-23 segment in the synovial tissue as described by
Kim et al. [46] and in peripheral blood of healthy controls [47].
Furthermore, it is of interest that autoantigen speciﬁc B cells using
VH3-23 have been described in healthy controls [48,49].
In the current study, analysis of Ig isotype usage showed that
while the most common isotype of the FcRL4þ B cells was IgG,
there was a signiﬁcant enrichment of IgA expressing B cells in the
FcRL4þ compared to the FcRL4- population (Fig. 1). This association
of FcRL4þ B cells with IgA is interesting in the light of current hy-
potheses of the pathogenesis of RA, in which clinical onset can be
preceded by mucosal inﬂammation in the gums, the gut and the
lungs [50e52]. Furthermore, the presence of IgA RF and/or IgA
ACPAs is predictive of aggressive disease in RA patients [53,54].
Further work is needed to investigate whether the IgA immune
response in the mucosa generates IgAþ FcRL4þ B cells, which later
migrate to the synovium, and contribute to local disease
progression.
A key aspect of this study was to determinewhether the FcRL4þ
B cells are a component of the autoimmune process driving RA.
With recent technological developments we were able to generate
recombinant monoclonal antibodies from variable regions of Ig
heavy and light chain genes of single B cells [29,30]. This approach
was recently used to show the presence of citrulline-reactive B cells
in the synovial ﬂuid of ACPAþ, but not in ACPA- patients [4,55,56].
Our data suggest that FcRL4þ B cells in the synovium are a
component of the citrulline-speciﬁc autoimmune response in RA.
Global investigation of the gene expression proﬁle of these cells
showed that FcRL4þ B cells have a distinct transcriptional proﬁle
lacking key regulators of differentiation towards plasma cells
(Fig. 5B and supplementary Fig. 2) [27]. Future research shouldaddress whether the FcRL4 expressing cells are in a transient stage
of differentiation and what their eventual fate is. It is possible that
under appropriate stimulatory conditions they will eventually
develop into plasma cells. Indeed, Ehrhardt et al. [41] have shown
that, if stimulated by IL-2 and IL-10, FcRL4þ B cells from tonsils can
be induced to produce antibodies.
Beyond antibody production, several functions of B cells have
been described, in particular the production of cytokines including
RANKL [13,23] as well as antigen presentation. Our previous work
has demonstrated that synovial FcRL4þ B cells express higher
levels of the classical costimulatory molecules, CD80 and CD86,
than FcRL4- B cells [14,41] suggesting that they may function as
antigen presenting cells. Given that the citrulline autoreactive B cell
receptors were overrepresented in the FcRL4þ B cell subset, these B
cells may cross-talk with local T cells and sustain an autoimmune
loop within the affected joint. Further work is needed to assess this
potential role. Furthermore, in addition to their role in the auto-
immune response directed against citrullinated proteins, their high
level of RANKL expression suggest that FcRL4þ B cells are a path-
ogenic B cell subset with a key role in joint destruction and
disability in RA.
5. Conclusions
B cells identiﬁed by their expression of IgA receptor FcRL4
accumulate both in the mucosa associated lymphatic tissue and in
the joints of RA patients. We have shown here that FcRL4þ B cells
isolated from the joints of RA patients display a signiﬁcantly
increased usage of the IgA isotype. This observation points towards
a potential role in the link between mucosal and joint autoimmu-
nity, which requires further investigation.
Importantly, FcRL4þ B cells isolated from the joints of patients
with RA are a component of the autoimmune response to citrulli-
nated autoantigens and their RANKL expression suggests that they
may contribute to joint damage through cytokine production.
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